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Plasmodium falciparum, is a protozoa that causes over 214 million cases of Malaria worldwide and the World 
Health Organization reported an estimated 438,000 deaths attributed to malaria in 2015. Current prevention 
strategies have reduced malaria cases but they are either costly, have poor efficacy or resistance has begun to 
develop. There is a global need for an effective pre-exposure prophylaxis treatment.  
The leading Malaria vaccine candidate is RTS,S which contains a monovalent Plasmodium falciparum 
circumsporozoite protein (CSP). The goal of this vaccine is to induce anti-CSP antibodies that would block 
sporozoite invasion of hepatocytes and thereby hinder parasite development into a blood-stage infection that 
causes malaria morbidity and mortality. Antibodies isolated from individuals who have received the RTS,S 
vaccine have been shown to prevent infection of hepatocytes, suggesting that CSP antibodies could be used 
prophylactically. However, phase III trial results of the vaccine have shown underwhelming efficacy in children.  
Growing resistance to transient protection strategies for travelers and low efficacy in vaccine trials suggest 
there is a need for a new treatment strategy. The generation of CSP specific human monoclonal antibodies 
(mAbs) would be useful as prevention especially for individuals that are temporarily exposed to Malaria in 
endemic regions such as travelers or military personnel. 
Isolation and production of therapeutic mAbs traditionally utilizes a handful of techniques including antibody 
engineering, phage display or hybridoma generation from transgenic mice. We have sorted antigen-specific 
memory B-cells from the peripheral blood of children naturally infected with malaria to isolate CSP-specific 
memory B-cells. These cells were individually sorted and PCR was performed to amplify antibody variable 
regions of the B-cell’s antibody mRNA. Samples that produced heavy and light chain antibody sequence were 
cloned and transiently expressed. We plan to characterize these mAbs for binding and neutralization of CSP to 
identify functional therapeutic mAbs. 
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